论文部分内容阅读
目的探讨复合辅酶在结肠癌根治术后患者接受奥沙利铂联合卡培他滨(XELOX)方案辅助化疗中的临床作用。方法将75例结肠癌根治术后患者随机分为试验组(37例)和对照组(38例),其中对照组仅接受XELOX方案辅助化疗;试验组接受XELOX方案辅助化疗的同时联合应用复合辅酶。观察两组治疗后患者生存状态以及不良反应发生情况。结果试验组和对照组患者的1年无疾病生存率分别为94.6%和94.7%,1年生存率均为100%。两组主要不良反应包括神经毒性、胃肠道反应、骨髓抑制、手足综合征、肝功能损伤、过敏反应和黏膜炎。与对照组相比,试验组中性粒细胞减少的发生率降低(P<0.05),而血小板减少以及ALT升高的发生率亦有降低趋势(P>0.05)。结论复合辅酶可有效减轻结肠癌根治术后患者接受XELOX方案辅助化疗所引起的不良反应。
Objective To investigate the clinical effect of coenzyme in the adjuvant chemotherapy of oxaliplatin combined with capecitabine (XELOX) in patients with colon cancer after radical operation. Methods Seventy-five patients with colon cancer undergoing radical operation were randomly divided into experimental group (37 cases) and control group (38 cases), in which the control group received only adjuvant chemotherapy with XELOX regimen. The experimental group received XELOX regimen combined with coenzyme . After treatment, the survival status of patients and the incidence of adverse reactions were observed. Results The one-year disease-free survival rates of patients in trial group and control group were 94.6% and 94.7%, respectively, and the 1-year survival rate was 100%. The two major adverse reactions included neurotoxicity, gastrointestinal reactions, myelosuppression, hand-foot syndrome, liver damage, allergic reactions and mucositis. Compared with the control group, the incidence of neutropenia decreased (P <0.05) and the incidence of thrombocytopenia and ALT decreased (P> 0.05). Conclusions Coenzyme can effectively reduce the adverse reactions caused by adjuvant chemotherapy with XELOX regimen in patients with colon cancer after radical operation.